Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer

Biochemical and Biophysical Research Communications
Theoni LeoutsakouAndreas Scorilas

Abstract

The SR-related-CTD-associated-factors (SCAFs) have the ability to interact with the C-terminal domain of the RNA polymerase II, linking this way transcription to splicing. SRA1 (SR-A1) gene, encoding for a human high-molecular weight SCAF protein, is located on chromosome 19, between the IRF3 and the R-RAS oncogene and it has been demonstrated from members of our group that SRA1 is constitutively expressed in most of the human tissues, while it is overexpressed in a subset of ovarian tumors. In this study, we examine the expression of SRA1 gene in 111 ovarian malignant tissues and in the human ovarian carcinoma cell lines OVCAR-3, TOV21-G, and ES-2, using a semi-quantitative RT-PCR method. SRA1 gene was overexpressed in 61/111 (55%) of ovarian carcinomas. This higher expression was positively associated to the size of the tumor (p<0.001), the grade and the stage of the disease (p=0.003 and p=0.006, respectively), and the debulking success (p<0.001). Kaplan-Meier survival analysis revealed that lower SRA1 expression increases the probability of both the longer overall and the progression free survival of the patients. Multivariate Cox regression analysis revealed that SRA1 may be used as an independent prognostic biomarker in ov...Continue Reading

References

Aug 25, 1995·Nucleic Acids Research·S F JamisonM A Garcia-Blanco
Apr 1, 1993·Trends in Biochemical Sciences·A L Greenleaf
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·A YuryevJ L Corden
Feb 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·R TackeJ L Manley
Feb 3, 1998·Molecular and Cellular Biology·W J Zhang, J Y Wu
May 9, 1998·Genes & Development·B J BlencoweP A Sharp
May 27, 1999·Genes & Development·Y HiroseJ L Manley
May 15, 2001·The EMBO Journal·I WetterbergU Skoglund
Jan 5, 2002·The Journal of Biological Chemistry·Francois RobertBenoit Coulombe
Mar 4, 2003·Molecular and Cellular Biology·Nanette RookeDouglas L Black
Jun 27, 2003·The Journal of Biological Chemistry·Delphine Galiana-ArnouxFabienne Del Gatto-Konczak
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Carla A BorgoñoDionyssios Katsaros
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George M YousefEleftherios P Diamandis
Feb 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas ScorilasEleftherios P Diamandis
Jun 24, 2004·Proceedings of the National Academy of Sciences of the United States of America·Yingqun HuangJoan A Steitz
Mar 9, 2005·Trends in Biochemical Sciences·Klemens J Hertel, Brenton R Graveley
Mar 31, 2005·Molecular and Cellular Biology·Demian CazallaJavier F Cáceres
May 20, 2005·Current Opinion in Cell Biology·David L Bentley
Jul 5, 2005·Biochemical and Biophysical Research Communications·Maria E KatsarouAndreas Scorilas
Jul 16, 2005·Biochemical and Biophysical Research Communications·Masayo OkumuraKazunori Imaizumi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.